<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112072</article-id><article-id pub-id-type="publisher-id">ACM-40419</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_10611685.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  低分子肝素治疗妊娠中晚期脐血流异常疗效观察
  Observation of Curative Effect of Low-Molecular-Weight Heparin on Abnormal Umbilical Blood Flow at Second and Third Trimester of Pregnancy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>婷婷</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>冰</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>丽丽</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>淑红</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>滨州医学院，山东 烟台</addr-line></aff><aff id="aff4"><addr-line>青岛大学附属烟台毓璜顶医院，山东 烟台</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>505</fpage><lpage>511</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评价低分子肝素(low molecular weight heparin, LMWH)在妊娠中晚期妊娠脐动脉血流异常治疗中的作用，寻找改善脐动脉血流异常的有效治疗方法。方法：采用随机数字分组法回顾性分析在青岛大学附属烟台毓璜顶医院2016年09月至2019年04月收治的106例妊娠中晚期脐动脉血流异常的患者分为两组，每组各53例。治疗组患者给予皮下注射低分子肝素钠5000IU q12h，吸氧3升/分bid治疗，对照组仅给予吸氧治疗。对两组患者妊娠期的脐动脉血流变化、分娩孕周、产时羊水情况及分娩后新生儿妊娠结局进行分析。结果：治疗组治疗前脐动脉收缩期最大血流速度(S)与舒张末期血流速度(D)的比值，即S/D比值为4.43 &#177; 1.01，治疗后3.21 &#177; 0.83，差异具有显著性(P &lt; 0.01)。对照组治疗前S/D比值3.78 &#177; 0.62，治疗后3.14 &#177; 0.52，差异具有显著性(P &lt; 0.01)。比较两组治疗前后S/D差值变化，治疗组S/D差值1.14 &#177; 0.98，对照组0.04 &#177; 0.66，相较对照组差异具有显著性(P &lt; 0.05)。治疗组脐动脉血流S/D比值下降率为100%，对照组为80.95%，两组比较差异有统计学意义(χ
   <sup>2</sup> = 6.78, P &lt; 0.05)；治疗组分娩孕周37.40 &#177; 2.32周，对照组38.21 &#177; 2.24周，两组比较差异具有显著性(P &lt; 0.05)；治疗组足月儿生后1分钟Apgar评分9.96 &#177; 0.19，对照组为9.89 &#177; 0.60，差异具有显著性(P &lt; 0.05)。治疗组产时羊水粪染的发生率为14.28%，对照组发生率22.22%，差异有统计学意义(χ
   <sup>2</sup> = 25.404, P &lt; 0.05)。当S/D ≥ 3.5时，围产儿预后不良发生率显著增加，发生新生儿肺炎、新生儿窒息的概率较S/D &lt; 3的新生儿发病率高，相比具有统计学意义(P &lt; 0.05)，需转入新生儿科治疗。当S/D ≥ 4时，新生儿小于胎龄儿的概率也明显增加，具有统计学意义(P &lt; 0.05)。结论：低分子肝素可改善新生儿结局，在妊娠中晚期脐动脉血流异常治疗中效果确切。
    Objective: To evaluate the role of low molecular weight heparin (LMWH) in the treatment of abnormal cord artery blood flow in late pregnancy, and to find effective treatment methods to improve cord arterial blood flow abnormalities. Methods: The clinical data of 106 consecutive patients with abnormal umbilical artery blood flow in the middle and late stages of pregnancy in the Affiliated Yantai Yuhuangding Hospital of Qingdao University from September 2016 to April 2019 were collected and analyzed retrospectively. The patients who had received subcutaneous injection of LMWH sodium 5000IU q12h and oxygen therapy at 3 L/min for 30 min, t.i.d. were defined as the therapy group (N = 53) and those received oxygen treatment only fell into the control group (N = 53). The changes in UMA indexes during pregnancy [including the ratio of the maximum systolic blood flow velocity to the end-diastolic blood flow velocity (S/D), resistance index (RI), and pulsation index (PI)], the gestational age, condition of amniotic fluid during delivery, and the outcome of newborns were analyzed. Results: In the therapy group, the S/D value reduced significantly from 4.43 &#177; 1.01 before treatment to 3.21 &#177; 0.83 after treatment (P &lt; 0.01). In the control group, the S/D value reduced significantly from 3.78 &#177; 0.62 before treatment to 3.14 &#177; 0.52 after treatment (P &lt; 0.01). The reduction in S/D value after treatment in the therapy group was 1.14 &#177; 0.98, which was significantly bigger than the 0.04 &#177; 0.66 reduction in the control group (P &lt; 0.05). The rate of UMA S/D reduction after treatment was 100% in the therapy group, with was significantly higher than the 80.95% in the control group (
   χ
   <sup>2</sup>
    = 4.39, P &lt; 0.05). The gestational age of therapy group (38.21 &#177; 2.24 weeks) was significantly longer than the control group (37.40 &#177; 2.32 weeks) (P &lt; 0.05). The 1-minute Apgar score in the therapy group was 9.96 &#177; 0.19, and that in the control group was 9.89 &#177; 0.60, the difference was significant (P &lt; 0.05). The incidence of meconium-stained amniotic fluid (MSAF) in the therapy group (14.28%) was significantly lower than that in the control group (22.22%) (
   χ
   <sup>2</sup>
     = 25.404, P &lt; 0.05). When S/D ≥ 3.5, the incidence of poor prognosis in perinatal infants increased significantly, with significantly increased probability of neonatal pneumonia and neonatal asphyxia, and requirement of transfer to the pediatrics department for further treatment (P &lt; 0.05). When S/D ≥ 4, the incidence of infants smaller than gestational age also increased significantly (P &lt; 0.05). Conclusion: LMWH could improve neonatal outcomes and was effective in the treatment of abnormal umbilical artery blood flow in the second and third trimester of pregnancy. 
  
 
</p></abstract><kwd-group><kwd>脐动脉血流，低分子肝素，产前保健, Umbilical Artery Blood Flow</kwd><kwd> Low Molecular Weight Heparin</kwd><kwd> Antenatal Care</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评价低分子肝素(low molecular weight heparin, LMWH)在妊娠中晚期妊娠脐动脉血流异常治疗中的作用，寻找改善脐动脉血流异常的有效治疗方法。方法：采用随机数字分组法回顾性分析在青岛大学附属烟台毓璜顶医院2016年09月至2019年04月收治的106例妊娠中晚期脐动脉血流异常的患者分为两组，每组各53例。治疗组患者给予皮下注射低分子肝素钠5000IU q12h，吸氧3升/分bid治疗，对照组仅给予吸氧治疗。对两组患者妊娠期的脐动脉血流变化、分娩孕周、产时羊水情况及分娩后新生儿妊娠结局进行分析。结果：治疗组治疗前脐动脉收缩期最大血流速度(S)与舒张末期血流速度(D)的比值，即S/D比值为4.43 &#177; 1.01，治疗后3.21 &#177; 0.83，差异具有显著性(P &lt; 0.01)。对照组治疗前S/D比值3.78 &#177; 0.62，治疗后3.14 &#177; 0.52，差异具有显著性(P &lt; 0.01)。比较两组治疗前后S/D差值变化，治疗组S/D差值1.14 &#177; 0.98，对照组0.04 &#177; 0.66，相较对照组差异具有显著性(P &lt; 0.05)。治疗组脐动脉血流S/D比值下降率为100%，对照组为80.95%，两组比较差异有统计学意义(c<sup>2</sup> = 6.78, P &lt; 0.05)；治疗组分娩孕周37.40 &#177; 2.32周，对照组38.21 &#177; 2.24周，两组比较差异具有显著性(P &lt; 0.05)；治疗组足月儿生后1分钟Apgar评分9.96 &#177; 0.19，对照组为9.89 &#177; 0.60，差异具有显著性(P &lt; 0.05)。治疗组产时羊水粪染的发生率为14.28%，对照组发生率22.22%，差异有统计学意义(c<sup>2</sup> = 25.404, P &lt; 0.05)。当S/D ≥ 3.5时，围产儿预后不良发生率显著增加，发生新生儿肺炎、新生儿窒息的概率较S/D &lt; 3的新生儿发病率高，相比具有统计学意义(P &lt; 0.05)，需转入新生儿科治疗。当S/D ≥ 4时，新生儿小于胎龄儿的概率也明显增加，具有统计学意义(P &lt; 0.05)。结论：低分子肝素可改善新生儿结局，在妊娠中晚期脐动脉血流异常治疗中效果确切。</p></sec><sec id="s2"><title>关键词</title><p>脐动脉血流，低分子肝素，产前保健</p></sec><sec id="s3"><title>Observation of Curative Effect of Low-Molecular-Weight Heparin on Abnormal Umbilical Blood Flow at Second and Third Trimester of Pregnancy<sup> </sup></title><p>Tingting Xu<sup>1</sup>, Bing Li<sup>2</sup>, Lili Zhu<sup>2</sup>, Shuhong Li<sup>3</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Binzhou Medical University, Yantai Shandong</p><p><sup>3</sup>The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai Shandong</p><p><img src="//html.hanspub.org/file/11-1571903x4_hanspub.png" /></p><p>Received: Jan. 7<sup>th</sup>, 2021; accepted: Jan. 29<sup>th</sup>, 2021; published: Feb. 19<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/11-1571903x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the role of low molecular weight heparin (LMWH) in the treatment of abnormal cord artery blood flow in late pregnancy, and to find effective treatment methods to improve cord arterial blood flow abnormalities. Methods: The clinical data of 106 consecutive patients with abnormal umbilical artery blood flow in the middle and late stages of pregnancy in the Affiliated Yantai Yuhuangding Hospital of Qingdao University from September 2016 to April 2019 were collected and analyzed retrospectively. The patients who had received subcutaneous injection of LMWH sodium 5000IU q12h and oxygen therapy at 3 L/min for 30 min, t.i.d. were defined as the therapy group (N = 53) and those received oxygen treatment only fell into the control group (N = 53). The changes in UMA indexes during pregnancy [including the ratio of the maximum systolic blood flow velocity to the end-diastolic blood flow velocity (S/D), resistance index (RI), and pulsation index (PI)], the gestational age, condition of amniotic fluid during delivery, and the outcome of newborns were analyzed. Results: In the therapy group, the S/D value reduced significantly from 4.43 &#177; 1.01 before treatment to 3.21 &#177; 0.83 after treatment (P &lt; 0.01). In the control group, the S/D value reduced significantly from 3.78 &#177; 0.62 before treatment to 3.14 &#177; 0.52 after treatment (P &lt; 0.01). The reduction in S/D value after treatment in the therapy group was 1.14 &#177; 0.98, which was significantly bigger than the 0.04 &#177; 0.66 reduction in the control group (P &lt; 0.05). The rate of UMA S/D reduction after treatment was 100% in the therapy group, with was significantly higher than the 80.95% in the control group (c<sup>2</sup>= 4.39, P &lt; 0.05). The gestational age of therapy group (38.21 &#177; 2.24 weeks) was significantly longer than the control group (37.40 &#177; 2.32 weeks) (P &lt; 0.05). The 1-minute Apgar score in the therapy group was 9.96 &#177; 0.19, and that in the control group was 9.89 &#177; 0.60, the difference was significant (P &lt; 0.05). The incidence of meconium-stained amniotic fluid (MSAF) in the therapy group (14.28%) was significantly lower than that in the control group (22.22%) (c<sup>2</sup> = 25.404, P &lt; 0.05). When S/D ≥ 3.5, the incidence of poor prognosis in perinatal infants increased significantly, with significantly increased probability of neonatal pneumonia and neonatal asphyxia, and requirement of transfer to the pediatrics department for further treatment (P &lt; 0.05). When S/D ≥ 4, the incidence of infants smaller than gestational age also increased significantly (P &lt; 0.05). Conclusion: LMWH could improve neonatal outcomes and was effective in the treatment of abnormal umbilical artery blood flow in the second and third trimester of pregnancy.</p><p>Keywords:Umbilical Artery Blood Flow, Low Molecular Weight Heparin, Antenatal Care</p><disp-formula id="hanspub.40419-formula9"><graphic xlink:href="//html.hanspub.org/file/11-1571903x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/27-3091157x8_hanspub.png" /> <img src="//html.hanspub.org/file/27-3091157x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>脐带作为母体与胎儿进行气体交换、供应营养物质及排出代谢产物的唯一通道，其血流动力学发生改变可反映胎儿、母体及胎盘的某些病理、生理变化。超声是目前应用最广泛的胎儿影像学监护方法 [<xref ref-type="bibr" rid="hanspub.40419-ref1">1</xref>]。超声可监测胎儿脐血流收缩期最大血流速度/舒张期末血流速度的比值(S/D)、阻力指数(RI)、搏动指数(PI)，从而达到在临床上评估胎儿预后的效果 [<xref ref-type="bibr" rid="hanspub.40419-ref2">2</xref>]。目前我国以S/D &gt; 3.0或RI &gt; 0.6作为晚孕胎儿宫内缺氧的指标 [<xref ref-type="bibr" rid="hanspub.40419-ref3">3</xref>]。胎盘内血液循环障碍可造成脐血管内血流的多普勒指标改变，严重时可出现舒张末期血流消失甚至反流，导致胎儿窘迫，甚至胎死宫内。因此，妊娠中晚期脐动脉血流异常患者及时采取有效治疗措施，对改善分娩结局尤为重要。有研究指出，低分子肝素具有改善子宫胎盘血液循环，改善血液高凝状态，降低血管阻力的效果 [<xref ref-type="bibr" rid="hanspub.40419-ref4">4</xref>]，这使得将低分子肝素用于治疗脐动脉血流异常成为可能。现选取2016年09月~2019年04月收治入院的共106例诊断为脐血流异常的妊娠25~40周孕妇进行回顾性对照研究(已通过青岛大学附属烟台毓璜顶医院伦理委员会审批)，效果明显，现将材料总结如下。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 一般资料</title><p>本组资料将106例2016年09月~2019年04月收治入院的诊断为脐血流异常(其脐动脉血流比值高于相应孕周第95百分位为脐血流异常)的妊娠25~40周孕妇共106例纳入研究，年龄24~34岁，平均30.05 &#177; 1.8岁，妊娠26~40周，平均31.95 &#177; 1.3周(见表1)。排除妊娠期高血压、妊娠期糖尿病、胎儿生长受限及妊娠合并症：高血压、心血管系统疾病、肾脏疾病及糖尿病；未应用影响血流变化的药物；且无使用低分子肝素禁忌症。随访到治疗组28例、对照组36例孕妇的分娩情况。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> General information for pregnant wome</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >年龄/岁</th><th align="center" valign="middle" >治疗孕周/周</th><th align="center" valign="middle" >治疗前S/D值</th><th align="center" valign="middle" >治疗前RI值</th><th align="center" valign="middle" >治疗前PI值</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >30 &#177; 3.70<sup>△</sup></td><td align="center" valign="middle" >29 &#177; 3.79<sup>△</sup></td><td align="center" valign="middle" >4.43 &#177; 1.01<sup>△</sup></td><td align="center" valign="middle" >0.75 &#177; 0.49<sup>△</sup></td><td align="center" valign="middle" >1.22 &#177; 0.22<sup>△</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >29 &#177; 4.02</td><td align="center" valign="middle" >34 &#177; 4.24</td><td align="center" valign="middle" >3.78 &#177; 0.32</td><td align="center" valign="middle" >0.77 &#177; 0.19</td><td align="center" valign="middle" >1.15 &#177; 0.25</td></tr></tbody></table></table-wrap><p>表1. 孕妇一般资料</p><p><sup>△</sup>：治疗组及对照组治疗前S/D比值、RI值、PI值、年龄及治疗孕周均无统计学意义(P &gt; 0.05)。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>对照组孕妇接受吸氧3升/分30分钟bid的基础治疗。治疗组孕妇在对照组基础上采用低分子肝素5000IU皮下注射(齐征，齐鲁制药有限公司，国药准字H20030429) q12h，连续治疗到S/D &lt; 3。</p></sec><sec id="s6_3"><title>2.3. 仪器及检测方法</title><p>受检孕妇排空膀胱，检查体位为半卧位，查清胎方位后，用彩色超声波多普勒诊断仪(美国GE-Voluson E10)检测胎儿脐血流。设置超声频率5 kHz，发射功率&lt;10 W/cm，于胎儿腹侧上下之间寻找脐动脉血流(UMA)信号，确诊胎儿脐动脉血流速度波形，可在显示屏上获得收缩期峰值一致的波形后，测量5个波形的脐血流收缩期最大血流速度/舒张期末血流速度的比值(S/D)、阻力指数(RI)、搏动指数(PI)。以上测量由同一超声检查医师完成，并将所有测得数据及图像储存于工作站中。</p></sec><sec id="s6_4"><title>2.4. 评价指标</title><p>该研究的评价指标为治疗前与分娩前脐动脉S/D、RI、PI，治疗时间，分娩孕周、产时羊水情况，新生儿生后1分钟、5分钟Apgar评分，脐带、新生儿体重、新生儿转儿科情况。患者分娩时在我院同一产房，均由两名同资历助产士及一名产科副主任医师共同完成分娩过程，并进行新生儿出生情况判定。不同孕周患者给予相同治疗，在治疗过程中，对患者的脐动脉血流状况进行动态监测，恢复正常即停止治疗，如仍异常，则继续治疗；患者脐血流正常后可出院门诊随诊，追踪出院患者至分娩前脐动脉血流值，随访未发现再次出现异常患者。</p></sec><sec id="s6_5"><title>2.5. 统计学方法</title><p>研究中所得到的相关数据采用SPSS 22.0统计学数据处理软件进行数据处理分析，计数资料以x &#177; s表示，采用t检验及曼–惠特尼U检验，多组间比较采用单因素方差分析，计数资料采用n (%)表示，行c<sup>2</sup>检验，P &lt; 0.05为差异具有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 胎儿脐血流的变化</title><p>治疗组治疗前S/D比值4.43 &#177; 1.01，治疗后3.21 &#177; 0.83，差异具有显著性(P &lt; 0.01)。对照组治疗前S/D比值3.78 &#177; 0.62，治疗后3.14 &#177; 0.52，差异具有显著性(P &lt; 0.01)。比较两组治疗前后差值，治疗组S/D差值1.14 &#177; 0.98，对照组0.04 &#177; 0.66，差异具有显著性(P &lt; 0.05)。两组PI及RI值治疗前后数值差异均具有显著性，但两组PI、RI差值，差异无统计学意义。此外，两组患者治疗前S/D、PI、RI值均无统计学意义(详见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Changes of cord blood flow after fetal data in two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="3"  >S/D</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >RI</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >PI</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >前后差</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >4.43 &#177; 1.01</td><td align="center" valign="middle" >3.21 &#177; 0.83<sup>△</sup></td><td align="center" valign="middle" >1.14 &#177; 0.98<sup>＊</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.75 &#177; 0.49</td><td align="center" valign="middle" >0.69 &#177; 0.49<sup>△</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.22 &#177; 0.22</td><td align="center" valign="middle" >1.02 &#177; 1.63<sup>△</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >3.78 &#177; 0.32</td><td align="center" valign="middle" >3.14 &#177; 0.52<sup>△</sup></td><td align="center" valign="middle" >0.04 &#177; 0.66</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.77 &#177; 0.19</td><td align="center" valign="middle" >0.67 &#177; 0.52</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.15 &#177; 0.25</td><td align="center" valign="middle" >1.05 &#177; 1.30<sup>△</sup></td></tr></tbody></table></table-wrap><p>表2. 两组胎儿脐动脉血流治疗后的变化</p><p><sup>*</sup>：治疗后与治疗前相比具有统计学意义(P &lt; 0.01)。</p><p><sup>△</sup>：治疗组与对照组比较差值具有统计学意义(P &lt; 0.05)。</p></sec><sec id="s7_2"><title>3.2. 临床治疗情况</title><p>治疗组所需治时间短于对照组(4.5 &#177; 1.7 vs 6.2 &#177; 1.1 d)，两组比较差异具有显著性(t = 5.32, P &lt; 0.05)。治疗组脐动脉血流S/D比值下降率为100%，对照组为80.95%。两组比较差异具有统计学意义(c<sup>2</sup> = 4.39, P &lt; 0.05)。</p></sec><sec id="s7_3"><title>3.3. 产时情况</title><p>治疗组分娩孕周38.21 &#177; 2.24周，对照组37.40 &#177; 2.32周，两组比较差异具有显著性(曼–惠特尼U检验，P &lt; 0.05)。产时治疗组羊水粪染的发生率为14.28%，相比较于对照组发生率22.22%，比较差异有统计学意义(c<sup>2</sup> = 25.404, P &lt; 0.05)。(详见表3)。</p></sec><sec id="s7_4"><title>3.4. 新生儿转归情况</title><p>记录两组新生儿生后1分钟、5分钟Apgar评分及出生体重发现，治疗组与对照组相比，治疗组足月儿1分钟Apgar评分9.96 &#177; 1.20，对照组足月儿为9.89 &#177; 0.50，其差异具有显著性(P &lt; 0.05)。新生儿5分钟Apgar评分及新生儿出生体重均无显著性(P &gt; 0.05) (详见表4)。此外，治疗组新生儿发生球拍状胎盘、新生儿脐带过短、脐带扭转、小于胎龄儿的发生率分别为7.14%、7.14%、0、10.71%，与对照组比较无统计学意义(P &lt; 0.05)。观察组转儿科的发生率为10.71％，对照组为27.78%，差异无统计学意义(c<sup>2</sup> = 2.833, P &gt; 0.05)新生儿转儿科产妇分娩前S/D值为4.64 &#177; 1.40，新生儿未转儿科产妇分娩前S/D为3.19 &#177; 0.62，差异具有统计学意义(t = 6.04, P &lt; 0.01)。(详见表5)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Gestational week during delivery and amniotic fluid fecal stainin</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >分娩孕周/周</th><th align="center" valign="middle" >羊水粪染发生率/%</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >38.21 &#177; 2.24<sup>△</sup></td><td align="center" valign="middle" >14.28<sup>*</sup></td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >37.40 &#177; 2.32</td><td align="center" valign="middle" >22.22</td></tr></tbody></table></table-wrap><p>表3. 产时分娩孕周及羊水粪染情况</p><p><sup>△</sup>：对照组与治疗组相比具有统计学意义(P &lt; 0.05)。</p><p><sup>*</sup>：治疗组与对照组相比具有统计学意义(P &lt; 0.05)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> The birth status of the two groups of newborn</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >1分钟Apgar评分</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >5分钟Apgar评分</th><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="2"  >新生儿出生体重/g</th></tr></thead><tr><td align="center" valign="middle" >未足月儿</td><td align="center" valign="middle" >足月儿</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >未足月儿</td><td align="center" valign="middle" >足月儿</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >未足月儿</td><td align="center" valign="middle" >足月儿</td></tr><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >9.50 &#177; 1.32</td><td align="center" valign="middle" >9.96 &#177; 1.20<sup>△</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >9.67 &#177; 0.81</td><td align="center" valign="middle" >9.96 &#177; 0.19</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2246 &#177; 616</td><td align="center" valign="middle" >3125 &#177; 673</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >9.96 &#177; 0.20</td><td align="center" valign="middle" >9.89 &#177; 0.50</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >10.00 &#177; 0.00</td><td align="center" valign="middle" >9.89 &#177; 0.60</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2124 &#177; 686</td><td align="center" valign="middle" >3213 &#177; 407</td></tr></tbody></table></table-wrap><p>表4. 两组新生儿产时状况</p><p><sup>△</sup>：治疗组与对照组相比具有统计学意义(P &lt; 0.05)。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Other conditions of the newbor</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >球拍状胎盘</th><th align="center" valign="middle" >脐带过短</th><th align="center" valign="middle" >脐带扭转</th><th align="center" valign="middle" >小于胎龄儿</th><th align="center" valign="middle" >新生儿转儿科</th></tr></thead><tr><td align="center" valign="middle" >治疗组</td><td align="center" valign="middle" >7.14%</td><td align="center" valign="middle" >7.14%</td><td align="center" valign="middle" >0</td><td align="center" valign="middle" >10.71%</td><td align="center" valign="middle" >10.71%</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >8.33%</td><td align="center" valign="middle" >8.33%</td><td align="center" valign="middle" >2.78%</td><td align="center" valign="middle" >22.22%</td><td align="center" valign="middle" >27.78%</td></tr></tbody></table></table-wrap><p>表5. 新生儿其他情况</p></sec><sec id="s7_5"><title>3.5. 不同S/D值与新生儿转归情况</title><p>记录孕妇分娩前S/D值，将S/D值分为&lt;3，3~3.5，3.5~4，4~4.5以及&gt;5共5个阶段，比较记录新生儿发生新生儿窒息、新生儿肺炎、小于胎龄儿不良转归发生概率。当S/D值为3.5~4时发生新生儿窒息(12.38%)、新生儿肺炎(7.62%)均较S/D值 &lt; 3时具有统计学意义(P &lt; 0.05)，当S/D值为4~4.5时，发生新生儿肺炎(4.76%)、小于胎龄儿(19.04%)较S/D &lt; 3时相比差异具有统计学意义(P &lt; 0.05) (详见表6)。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Different S/D values of cord blood flow and perinatal outcom</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >脐血流S/D值</th><th align="center" valign="middle"  colspan="3"  >围产儿不良结局(%)</th></tr></thead><tr><td align="center" valign="middle" >新生儿窒息</td><td align="center" valign="middle" >新生儿肺炎</td><td align="center" valign="middle" >小于胎龄儿</td></tr><tr><td align="center" valign="middle" >&lt;3</td><td align="center" valign="middle" >7.62</td><td align="center" valign="middle" >2.83</td><td align="center" valign="middle" >9.52</td></tr><tr><td align="center" valign="middle" >3~3.5</td><td align="center" valign="middle" >14.29</td><td align="center" valign="middle" >3.81</td><td align="center" valign="middle" >4.76</td></tr><tr><td align="center" valign="middle" >3.5~4</td><td align="center" valign="middle" >12.38<sup>△</sup></td><td align="center" valign="middle" >7.62<sup>△</sup></td><td align="center" valign="middle" >14.29</td></tr><tr><td align="center" valign="middle" >4~4.5</td><td align="center" valign="middle" >3.81</td><td align="center" valign="middle" >4.76<sup>△</sup></td><td align="center" valign="middle" >19.04<sup>△</sup></td></tr><tr><td align="center" valign="middle" >&gt;4.5</td><td align="center" valign="middle" >19.04</td><td align="center" valign="middle" >2.83</td><td align="center" valign="middle" >2.83</td></tr></tbody></table></table-wrap><p>表6. 不同脐血流S/D值与围产儿结局</p><p><sup>△</sup>：与脐血流S/D值&lt;3相比较有统计学意义(P &lt; 0.05)。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>脐动脉连接在胎儿与胎盘之间，是胎儿与母体之间进行物质交换的重要通道，脐动脉内血流的三项主要多普勒指标能够反映出胎儿胎盘的供血情况，血流阻力越大，血流量越小。脐血流收缩期最大血流速度/舒张期末血流速度的比值(S/D)可体现胎儿心动周期中血流速度的变化情况，通过分析脐动脉收缩期最大血流速度与舒张期最低血流速度比值可了解胎儿心脏收缩功能及外周血管的阻力 [<xref ref-type="bibr" rid="hanspub.40419-ref5">5</xref>]。子宫胎盘循环内的血流阻力向上游传递到子宫动脉，并且可以测量为增加的搏动指数(PI)或阻力指数(RI) [<xref ref-type="bibr" rid="hanspub.40419-ref6">6</xref>]。S/D主要反映了胎盘末梢循环阻抗和胎盘血流的灌注量，S/D升高提示血流灌注量减少，胎盘阻力增加，功能降低。脐动脉血流S/D正常情况下应在妊娠第30周下降至3.0以下，而S/D也是衡量胎儿是否发生宫内窘迫的一项重要指标。正常妊娠时随着孕龄的增加，胎盘循环阻力降低，胎盘血流灌注量渐渐增多。正常胎儿生长和发育取决于胎盘绒毛内通过的血流量，产科合并症(妊娠合并甲状腺功能亢进、妊娠合并糖尿病、妊娠合并贫血等)和并发症(妊娠期高血压疾病、前置胎盘、胎盘早剥、妊娠期胆汁淤积综合征、羊水量异常等)亦可使胎盘绒毛和绒毛血管分支减少，绒毛间质血管所占比增加、纤维物质沉积及血栓闭塞至血栓形成等 [<xref ref-type="bibr" rid="hanspub.40419-ref7">7</xref>]，可造成胎儿–胎盘循环阻力增加，从而使脐动脉血流量减少，血管阻力增大，导致胎盘供血不足从而致使胎儿在宫内缺血、缺氧，易发生胎儿宫内窘迫，在超声下表现为胎儿脐动脉血流指数增高 [<xref ref-type="bibr" rid="hanspub.40419-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.40419-ref9">9</xref>]。</p><p>低分子肝素是由标准肝素经酶解或化学解聚过程产生的由12~18个糖单位组成的葡糖胺聚糖，近年研究发现，低分子肝素主要是通过抑制与凝血酶IIa结合及凝血因子Xa活性，从而快速抑制血栓形成 [<xref ref-type="bibr" rid="hanspub.40419-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.40419-ref11">11</xref>]。它具有抗炎、抗凝、抗栓作用，能有效保护血管内皮细胞，降低血液黏稠度及改善胎盘微循环 [<xref ref-type="bibr" rid="hanspub.40419-ref12">12</xref>]。另外，低分子肝素可对血小板和血管内皮进行促进血管内皮细胞释放组织因子途径抑制物(Tissue factor pathway inhihito, TFPI)，对抗凝血因子Xa活性进行直接抑制，对内源性组织因子进行中和 [<xref ref-type="bibr" rid="hanspub.40419-ref13">13</xref>]。肝素可对细胞因子或激素与其受体结合进行抑制，降低周血管阻力，降低脐动脉S/D [<xref ref-type="bibr" rid="hanspub.40419-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.40419-ref15">15</xref>]，改善不良母儿预后。李玲玲等 [<xref ref-type="bibr" rid="hanspub.40419-ref16">16</xref>] 研究发现低分子肝素治疗后胎儿生长受限(fetal growth restriction, FGR)的胎盘绒毛毛细血管的通透性有明显增加，胶原纤维减少。因此，低分子肝素可改善FGR胎盘绒毛及绒毛间血管通透性，使绒毛间质血管间物质转运得到改善。</p><p>本研究应用主要是根据低分子肝素抗炎、抗凝、抗免疫及保护血管内皮作用，而采取治疗妊娠中晚期脐动脉血流异常情况。本研究结果显示：与仅吸氧治疗的对照组相比，采用低分子肝素的治疗组患者的S/D下降差值有显著性意义(P &lt; 0.01)，治疗有效率显著增加，用药疗程更短，治疗组所需治疗时间短于对照组(4.5 &#177; 1.7 vs 6.2 &#177; 1.1 d, P &lt; 0.05)。使用低分子肝素能更有效地降低脐血流压力，分娩时羊水粪染的发生率降低(P &lt; 0.05)。统计发现，足月儿生后1分钟Apgar评分更高(P &lt; 0.05)，1分钟Apgar评分反应胎儿宫内的情况，可能与低分子肝素治疗后绒毛间质血管间物质转运得到改善有关。其他功能指标对比，差异则并不明显。可进一步扩大样本验证结果。</p><p>本研究发现，当S/D ≥ 3.5时，围产儿预后不良发生率显著增加，发生新生儿肺炎、新生儿窒息的概率较S/D &lt; 3高，相比具有统计学意义(P &lt; 0.05)，需转入新生儿科进一步治疗。当S/D ≥ 4时，小于胎龄儿发生率也明显增加，具有统计学意义(P &lt; 0.05) (见图5)，与既往研究得出结论基本一致。肖学茹 [<xref ref-type="bibr" rid="hanspub.40419-ref17">17</xref>]<sup> </sup> 等研究显示当脐血流值S/D ≥ 4的孕妇，发生胎儿生长受限、羊水污染、羊水过少、新生儿窒息、小于胎龄儿的逐渐增加；当脐血流值S/D ≥ 5，发生胎死宫内的概率明显增多。与本研究有一定差异原因与治疗组S/D值平均值差异及患儿预后随访问题，应进一步扩大样本。因此，当脐血流值S/D ≥ 3.5，应严密监测胎儿宫内情况，尽早给予适当的治疗，适时终止妊娠，从而减少围生儿不良结局的发生 [<xref ref-type="bibr" rid="hanspub.40419-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.40419-ref19">19</xref>]。</p><p>低分子肝素不致畸且不通过胎盘 [<xref ref-type="bibr" rid="hanspub.40419-ref4">4</xref>]。美国食品与药品管理局(FDA)将其定为妊娠期B类药物。本研究发现当S/D ≥ 3.5时围产儿预后不良发生率显著增加，因此对于S/D ≥ 3.5孕妇适时给予低分子肝素治疗，对降低围生期及新生儿不良结局发生率有一定的临床意义。</p></sec><sec id="s9"><title>基金项目</title><p>国家卫生和计划生育委员会生育调控技术重点开放实验室编号：2018KF005题目：circHIPK3调控Wnt通路参与不明原因复发性流产发病机制研究。</p></sec><sec id="s10"><title>文章引用</title><p>徐婷婷,李 冰,朱丽丽,李淑红. 低分子肝素治疗妊娠中晚期脐血流异常疗效观察Observation of Curative Effect of Low-Molecular-Weight Heparin on Abnormal Umbilical Blood Flow at Second and Third Trimester of Pregnancy[J]. 临床医学进展, 2021, 11(02): 505-511. https://doi.org/10.12677/ACM.2021.112072</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40419-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">杨凤娟. 孕晚期彩超血流参数监测对高危妊娠结局的预测价值[J]. 中国数字医学, 2017, 12(4): 82-84.</mixed-citation></ref><ref id="hanspub.40419-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Morales-Roselló, J., Khalil, A., Morlando, M., Papageorghiou, A., Bhide, A. and Thilaganathan, B. (2014) Changes in Fetal Doppler Indices as a Marker of Failure to Reach Growth Potential at Term. Ultrasound in Obstetrics &amp; Gynecology, 43, 303-310. &lt;br&gt;https://doi.org/10.1002/uog.13319</mixed-citation></ref><ref id="hanspub.40419-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">周永昌, 郭万学. 超声医学[M]. 第6版. 北京: 人民军医出版社, 2011: 1247-1249.</mixed-citation></ref><ref id="hanspub.40419-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">袁燕, 郑九生. 低分子肝素在产科应用中的研究进展[J]. 现代妇产科进展, 2016, 25(8): 631-632.</mixed-citation></ref><ref id="hanspub.40419-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">骆伟萍, 傅晓凤, 吴亚萍. 胎儿电子监护联合脐血流S/D比值预测胎儿宫内窘迫的临床意义[J]. 浙江医学, 2015, 37(12): 1102-1103.</mixed-citation></ref><ref id="hanspub.40419-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Khong, S.L., Kane, S.C., Brennecke, S.P. and da Silva Costa, F. (2015) First-Trimester Uterine Artery Doppler Analysis in the Prediction of Later Pregnancy Complications. Disease Markers, 2015, Article ID: 679730.  
&lt;br&gt;https://doi.org/10.1155/2015/679730</mixed-citation></ref><ref id="hanspub.40419-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Sachin, K., Saakshi, C., Santosh, Y., et al. (2017) Role of Color Doppler Flowmetry in Prediction of Intrauterine Growth Retardation in High-Risk Pregnancy. Cureus, 9, e1827. &lt;br&gt;https://doi.org/10.7759/cureus.1827</mixed-citation></ref><ref id="hanspub.40419-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Morris, R.K., Malin, G., Robson, S.C., et al. (2011) Fetal Umbilical Artery Doppler to Predict Compromise of Fetai/Neonatal Wellbeing in a High-Risk Population Systematic Review and Bivariate Meta-Analysis. Ultrasound in Obstetrics &amp; Gynecology, 37, 135-142. &lt;br&gt;https://doi.org/10.1002/uog.7767</mixed-citation></ref><ref id="hanspub.40419-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sled, J.G., Stortz, G., Cahill, L.S., et al. (2019) Reflected Hemodynamic Waves Influence the Pattern of Doppler Ultrasound Waveforms along the Umbilical Arteries. The American Journal of Physiology-Heart and Circulatory Physiology, 316, H1105-H1112. &lt;br&gt;https://doi.org/10.1152/ajpheart.00704.2018</mixed-citation></ref><ref id="hanspub.40419-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cetin, K., Enis, O., Resul, K., et al. (2018) Early Low Molecular Weight Heparin for Postpartum Hemorrhage in Women with Pre-Eclampsia. Is It Effective to Prevent Consumptive Coagulopathy? Journal of Maternal-Fetal and Neonatal Medicine, 33, 410-414.</mixed-citation></ref><ref id="hanspub.40419-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">de Almeida, S.F.R., Dutra, A.R., Marcon de, O.V., et al. (2017) Doppler Velocimetry in Fetal Rats Exposed to Enoxaparin and Unfractionated Heparin (UFH) during Pregnancy. Acta Cirúrgica Brasileira, 32, 325-333.  
&lt;br&gt;https://doi.org/10.1590/s0102-865020170050000001</mixed-citation></ref><ref id="hanspub.40419-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">McLaughlin, K., Baczyk, D., Potts, A., et al. (2017) Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of Preeclampsia. Hypertension, 69, 180-188.  
&lt;br&gt;https://doi.org/10.1161/HYPERTENSIONAHA.116.08298</mixed-citation></ref><ref id="hanspub.40419-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Abheiden, C., Van Hoorn, M.E., Hague, W.M., et al. (2016) Does Low-Molecular-Weight Heparin Influence Fetal Growth or Uterine and Umbilical Arterial Doppler in Women with a History of Early-Onset Uteroplacental Insufficiency and an Inheritable Thrombophilia? Secondary Randomised Controlled Trial Results. BJOG, 123, 797-805.  
&lt;br&gt;https://doi.org/10.1111/1471-0528.13421</mixed-citation></ref><ref id="hanspub.40419-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Khong, S.L., Kane, S.C., Brennecke, S.P., et al. (2015) First-Trimester Uterine Artery Doppler Analysis in the Prediction of Later Pregnancy Complications. Disease Markers, 2015, Article ID: 679730.  
&lt;br&gt;https://doi.org/10.1155/2015/679730</mixed-citation></ref><ref id="hanspub.40419-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">李玉娣. 低分子肝素治疗妊娠中晚期脐动脉血流异常临床观察[J]. 深圳中西医结合杂志, 2018, 28(1): 164-165.</mixed-citation></ref><ref id="hanspub.40419-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李玲玲, 张龑. 低分子肝素对胎儿生长受限患者胎盘超微结构及血管内皮生长因子表达的影响[J]. 中国妇产科临床杂志, 2012, 13(6): 440-442.</mixed-citation></ref><ref id="hanspub.40419-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">肖学茹, 张陈彦, 孙东霞, 等. 妊娠中期脐动脉血流S/D值变化与围产儿不良结局的关系[J]. 山东医药, 2015, 55(30): 51-52.</mixed-citation></ref><ref id="hanspub.40419-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Silver, R.M. (2018) Examining the Link between Placental Pathology, Growth Restriction, and Stillbirth. Best Practice &amp; Research Clinical Obstetrics &amp; Gynaecology, 49, 89-102. &lt;br&gt;https://doi.org/10.1016/j.bpobgyn.2018.03.004</mixed-citation></ref><ref id="hanspub.40419-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lefkou, E., Mamopoulos, A., Dagklis, T., et al. (2016) Pravastatin Improves Pregnancy Outcomes in Obstetric Antiphospholipid Syndrome Refractory to Antithrombotic Therapy. Journal of Clinical Investigation, 126, 2933-2940.  
&lt;br&gt;https://doi.org/10.1172/JCI86957</mixed-citation></ref></ref-list></back></article>